| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2009;120:318-325.)
© 2009 American Heart Association, Inc.
Molecular Cardiology |
Results in Contractile DysfunctionFrom the Department of Physiology and Biophysics and Institute of Molecular Cardiology (Z.L., W.W., R.T.M., E.E., I.S.C., R.Z.L.) and Department of Medicine (Y.P.J., L.M.B., R.Z.L.), Stony Brook University, Stony Brook, NY; Department of Cardiac Surgery, Central South University, Changsha, China (X.H.X.); and Department of Veterans Affairs Medical Center, Northport, NY (R.Z.L.).
Correspondence to Dr Richard Z. Lin, Division of Hematology/Oncology, HSC T15–045, Stony Brook University, Stony Brook, NY 11794–8151. E-mail richard.lin{at}sunysb.edu
Received August 14, 2009; accepted May 5, 2009.
Background— Phosphoinositide 3-kinase (PI3K) p110
plays a key role in insulin action and tumorigenesis. Myocyte contraction is initiated by an inward Ca2+ current (ICa,L) through the voltage-dependent L-type Ca2+ channel (LTCC). The aim of this study was to evaluate whether p110
also controls cardiac contractility by regulating the LTCC.
Methods and Results— Genetic ablation of p110
(also known as Pik3ca), but not p110β (also known as Pik3cb), in cardiac myocytes of adult mice reduced ICa,L and blocked insulin signaling in the heart. p110
-null myocytes had a reduced number of LTCCs on the cell surface and a contractile defect that decreased cardiac function in vivo. Similarly, pharmacological inhibition of p110
decreased ICa,L and contractility in canine myocytes. Inhibition of p110β did not reduce ICa,L.
Conclusions— PI3K p110
but not p110β regulates the LTCC in cardiac myocytes. Decreased signaling to p110
reduces the number of LTCCs on the cell surface and thus attenuates ICa,L and contractility.
Related Article:
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |